TASADENOTUREV for High grade malignant brain neoplasm | High-grade glioma | Ependymoma | Embryonal CNS tumor (medulloblastoma/ATRT/ETMR/pineoblastoma)

Inclusion criteria

• {"criterion_text":"- The participant or participant’s parents or legally acceptable representatives (if applicable) provides written informed consent for the trial and the pediatric participant provides written assent, where applicable, based on age and country requirements.\n- Autologous Stem Cell Transplantation: patients must be ≥ 3 months post-transplant prior to entry of the study.\n- Patients must be fully recovered from all acute treatment related toxicities of all prior therapies.\n- Laboratory test: adequate hematological (platelets ≥ 100x10⁹/L, neutrophils ≥ 1.0x10⁹/L, hemoglobin ≥ 5,6 mmol/L), renal function (creatinine <1.5 times ULN) and liver function (≤3 times ULN) values.\n- Negative pregnancy test for female participants of child-bearing potential, where child-bearing potential is defined as a fertile female who is pubertal or post-pubertal and not permanently sterile (hysterectomy, bilateral salpingectomy, bilateral oophorectomy).\n- Female participants of child-bearing potential, who are sexually active, agree to use acceptable birth control starting at informed consent and continuing for at least 120 days after DNX-2401 administration. Male participants agree to use acceptable birth control starting at informed consent and continuing for at least 90 days after DNX-2401 administration.\n- Patients with recurrent or refractory high grade malignant brain tumors (high grade glioma, embryonal CNS tumors [medulloblastomas, ATRT, EMTR, pineoblastoma], and ependymomas) diagnosis based on initial histopathological diagnosis and further clinical and radiological follow-up, in whom gross total resection is not feasible, and with a life expectancy of at least 16 weeks at the time of consent.\n- Recurrences within the radiation field will be considered if there is confirmed growth of the lesion in two consecutive MRI or if they occur at least 12 weeks after completion of radiation therapy, or if there is clear histopathological confirmation of tumor recurrence.\n- Male and female participants age ≥ 1 years and ≤ 25 years.\n- A single measurable lesion longer than 10 mm in two perpendicular diameters, considered by the investigator to be accessible for safe stereotactic biopsy and virus injection.\n- Lansky Performance Status (LPS) ≥ 60 for participants < 16 years, or Karnofsky Performance Status (KPS) ≥ 60 for participants ≥ 16 years.\n- No other chemotherapy or immunotherapy in the 4 weeks before inclusion.\n- Steroids: free off or requiring decreasing or stable corticosteroid dose (≥ 0.05 mg/kg dexamethasone daily, or equivalent for other steroids) in the 2 weeks before DNX-2401 administration.\n- Radiation: no craniospinal irradiation, total body irradiation nor focal irradiation in the 6 weeks before inclusion."}

Exclusion criteria

• {"criterion_text":"- Any medical or psychological condition or disease that might interfere with the subject’s ability to participate or give informed consent (if older than 16 years).\n- Life or life-attenuated vaccinations within 30 days prior to DNX-2401 administration and while participating in the study. Killed vaccines are permitted.\n- Prior participant in experimental viral therapy.\n- Inability to undergo MRI scans for any reason.\n- Pregnancy or breastfeeding.\n- Spinal location, or lesions considered risky for stereotactic injection of virus or that might favor entrance of the virus in the ventricular system.\n- Any treatment outside the allowable guidelines outlined in the inclusion criteria.\n- Severe acute infection or intercurrent medical condition including, but not limited to severe renal, hepatic, heart or bone marrow failure that based on investigator discretion do not permit inclusion in the study.\n- Subjects with immunodeficiency or autoimmune conditions, active hepatitis or known HIV. No testing for Hepatitis B, Hepatitis C and HIV is required unless mandated by local health authority.\n- Subjects with another primary malignancy.\n- Prior history of encephalitis, multiple sclerosis or other CNS infections or primary CNS disease that would interfere with evaluation.\n- Li-Fraumeni Syndrome or a known germ line deficit in the retinoblastoma gene or its related pathways.\n- Concurrent therapy with any antiviral drug or any immunosuppressive drug (except steroids)."}

Primary endpoints

• {"endpoint_text":"- Overall response rate (ORR), defined as the percentage of patients with complete response (CR), partial response (PR), or stable disease (SD for at least 12 weeks) as best response according to RAPNO criteria.","definition_or_measurement_approach":"Defined as the percentage of patients with complete response (CR), partial response (PR), or stable disease (SD for at least 12 weeks) as best response according to RAPNO criteria."}

Secondary endpoints

• {"endpoint_text":"- Number of AEs and SAEs per NCI-CTCAE criteria in first 12 weeks after DNX-2401 administration.","definition_or_measurement_approach":"Count and classification of adverse events and serious adverse events using NCI-CTCAE criteria during the first 12 weeks after administration."}
• {"endpoint_text":"- Time to response.","definition_or_measurement_approach":"Time from DNX-2401 administration to first documented tumor response (per imaging/criteria)."}
• {"endpoint_text":"- Duration of response.","definition_or_measurement_approach":"Time from first documented response to progression or death."}
• {"endpoint_text":"- PFS, OS: 6- and 12- month PFS and OS rates.","definition_or_measurement_approach":"Progression-free survival and overall survival rates at 6 and 12 months (measured in months and percentages)."}
• {"endpoint_text":"- LPS/KPS and QoL (PedsQL™ Generic Score Scale) parameters compared to baseline.","definition_or_measurement_approach":"Changes in Lansky Performance Score (LPS) or Karnofsky Performance Status (KPS) and quality of life measured using the PedsQL™ Generic Score Scale compared with baseline."}

Netherlands

Earliest CTIS Part Ii Submission Date

10-03-2026

Latest Decision Or Authorization Date

23-03-2026

Processing Time Days

13

Number Of Sites

2

Number Of Participants

19

Spain

Earliest CTIS Part Ii Submission Date

25-02-2026

Latest Decision Or Authorization Date

20-04-2026

Processing Time Days

54

Number Of Sites

1

Number Of Participants

20

Primary sponsor

Full Name

Clinica Universidad De Navarra

Organisation Type

Hospital/Clinic/Other health care facility

Country Of Registered Address

Spain